Hastim is entering a new era of its development with the establishment of a clinical trial program with its therapeutic vaccine to confirm the excellent results obtained in animals in humans.
An innovative and unique treatment
Hastim’s innovation is an immunostimulant treatment based on the ability of hydroxyapatite to capture tumour proteins and trigger appropriate immune defence.
This concept of anti-tumour immunotherapy aims to regenerate, since it has become deficient, an effector and memory lymphocyte response against certain dominant antigens of the patient’s cancer.
Immunotherapy is a rapidly expanding pathway because it demonstrates better selectivity and lower side effects.
However, where existing immunotherapeutic treatments remain complex, perfectible into still very costly approaches, such as monoclonal antibodies and CAR-T cells, Hastim’s innovation represents a true technological breakthrough.
Hydroxyapatite is a mineral with biomimetic properties in permanent interface with living tissue to reset life, both in orthopaedics and oncology.
A natural material present in the bone, hydroxyapatite has the ability to capture the body’s tumour proteins. It makes them detectable, often apart from a tumour environment that protects cancer cells, by the immune system , which will then reactivate itself to fight the tumour cells that have emitted them.
It has special surface characteristics that give it adsorption properties, especially with protein compounds.
Hydroxyapatite is a healthy vector used as a separator for single and double stranded DNA chains that provides for protein purification.
It is this property that is used in the preparation of the treatment developed by Hastim in immuno-oncology